Our novel GABAA α5 discovery program has potential to treat aMCI, autism and schizophrenia.
AgeneBio has a novel GABAA α5 small molecule program in late discovery stage with potential to address unmet needs for several diseases of the central nervous system including aMCI, autism and schizophrenia.
Our GABAA α5 Positive Allosteric Modulator (PAM) program builds on the science developed for the AGB101 program. With a high density of GABAA α5 receptors in the hippocampus, compounds that act as GABAA α5 PAMs are well positioned to attenuate and control hippocampal overactivity. Proof of biology studies demonstrate that GABAA α5 PAMs from multiple structural classes occupy GABAA α5 receptors in the hippocampus and improve memory impairment in aged animals.
Learn more in our publications.
The technology and patents behind AgeneBio’s early-stage program were discovered and initially developed by researchers at Johns Hopkins University, including the company’s founder and chief scientific officer, Michela Gallagher, PhD. We expect to submit our IND for this development asset in 2017.